Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today

What Happened?

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 2% in the morning session after an insider filed to sell a substantial block of shares. 

A regulatory filing showed a plan to sell 154,958 shares, with a total market value of about $8.94 million. Large sales by insiders can often worry investors. When a key person within a company sells a significant amount of stock, the market may interpret it as a lack of confidence in the company's future performance. This can lead other investors to sell their shares, putting downward pressure on the stock price. The news of this planned sale appeared to have cast a shadow over the stock.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Hims & Hers Health? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Hims & Hers Health’s shares are extremely volatile and have had 99 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 4 days ago when the stock gained 3.5% as investors focused on the company's strong growth prospects, which appeared to overshadow recent regulatory challenges. 

The telehealth company showed compelling potential, with earnings posting a very large increase over the previous year and revenue forecasted to grow faster than the broader U.S. market. This positive outlook, however, was set against a backdrop of recent headwinds. The FDA had issued a warning concerning misbranded compounded drugs. 

Additionally, a partnership with pharmaceutical giant Novo Nordisk was terminated because of safety concerns, a development that had previously affected investor confidence. Despite these issues, the market seemed to prioritize the company's expansion in men's health and its fundamental growth story.

Hims & Hers Health is up 126% since the beginning of the year, but at $56.93 per share, it is still trading 17.2% below its 52-week high of $68.74 from February 2025. Investors who bought $1,000 worth of Hims & Hers Health’s shares 5 years ago would now be looking at an investment worth $5,286.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.